替格瑞洛对冠心病患者血浆内脂素、血清氧化应激标志物水平及疗效的影响

Influence of ticagrelor on levels of plasma visfatin and serum oxidative stress biomarkers and curative effect in patients with coronary heart disease

目的探讨替格瑞洛对冠状动脉粥样硬化性心脏病(冠心病)患者血浆内脂素、血清氧化应激标志物水平及疗效的影响。方法选择2015年9月至2017年9月于西安交通大学第二附属医院收治的冠心病患者95例,随机分为观察组(n=48)和对照组(n=47)。对照组给予常规氯吡格雷治疗,观察组为替格瑞洛治疗,其他治疗方案两组相同,干预时间均为12周。治疗结束后比较两组患者血浆内脂素、血清氧化应激标志物水平、疗效及不良反应的发生情况。结果治疗后,观察组总有效率89.58%,高于对照组的70.21%(P<0.05);两组治疗后的晚期蛋白质氧化产物(AOPP)、超氧化物歧化酶(SOD)、丙二醛(MDA)和晚期糖基化终末产物(AGEs)水平比较,观察组均显著优于对照组(P<0.01);观察组治疗后的血浆内脏脂肪素水平显著低于对照组(P<0.01)。观察组不良反应发生率为6.25%;对照组为21.28%,观察组不良反应发生率明显低于对照组(P<0.05)。结论在冠心病患者中应用替格瑞洛治疗效果显著,可有效改善血浆内脂素、血清氧化应激标志物水平,减少不良反应。

Objective To discuss the influence of ticagrelor on levels of plasma visfatin and serum oxidative stress biomarkers and curative effect in patients with coronary heart disease(CHD).Methods CHD patients(n=95)were chosen from the Second Affiliated Hospital of Xi’an Jiaotong University from Sept.2015 to Sept.2017,and then divided randomly into observation group(n=48)and control group(n=47).Besides of the same therapeutic schemes,the control group was conventionally treated with clopidogrel and observation group was treated with ticagrelor for 12 weeks.The levels of plasma visfatin and serum oxidative stress biomarkers,curative effect and incidence of adverse reactions were compared between 2 groups after the treatment finished.Results The total effective rate was 89.58% in observation group and 70.21%in control group(P<0.05).The comparisons in levels of advanced oxidation protein product(AOPP),superoxide dismutase(SOD),malondialdehyde(MDA)and advanced glycation end products(AGEs)showed that observation group was significantly superior to control group after treatment(P<0.01).The level of plasma visfatin was significantly lower in observation group than that in control group after treatment(P<0.01).The incidence rates of adverse reactions were 6.25%in observation group and 21.28%in control group(P<0.05).Conclusion Ticagrelor has significant curative effect,and it can effectively improve the levels of plasma visfatin and serum oxidative stress biomarkers and reduce adverse reactions in CHD patients.